These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
553 related articles for article (PubMed ID: 20130650)
21. The CML stem cell: evolution of the progenitor. Stuart SA; Minami Y; Wang JY Cell Cycle; 2009 May; 8(9):1338-43. PubMed ID: 19342894 [TBL] [Abstract][Full Text] [Related]
22. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147 [TBL] [Abstract][Full Text] [Related]
23. Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia. Sears D; Luong P; Yuan M; Nteliopoulos G; Man YK; Melo JV; Basu S Cell Death Dis; 2010 Nov; 1(11):e93. PubMed ID: 21368869 [TBL] [Abstract][Full Text] [Related]
24. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Helgason GV; Karvela M; Holyoake TL Blood; 2011 Aug; 118(8):2035-43. PubMed ID: 21693757 [TBL] [Abstract][Full Text] [Related]
25. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib. Lee J; Shen P; Zhang G; Wu X; Zhang X Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011 [TBL] [Abstract][Full Text] [Related]
26. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Kobayashi CI; Takubo K; Kobayashi H; Nakamura-Ishizu A; Honda H; Kataoka K; Kumano K; Akiyama H; Sudo T; Kurokawa M; Suda T Blood; 2014 Apr; 123(16):2540-9. PubMed ID: 24574458 [TBL] [Abstract][Full Text] [Related]
27. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis. Corrado C; Flugy AM; Taverna S; Raimondo S; Guggino G; Karmali R; De Leo G; Alessandro R PLoS One; 2012; 7(8):e42310. PubMed ID: 22879938 [TBL] [Abstract][Full Text] [Related]
28. Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. Kikuchi S; Nagai T; Kunitama M; Kirito K; Ozawa K; Komatsu N Cancer Sci; 2007 Dec; 98(12):1949-58. PubMed ID: 17900262 [TBL] [Abstract][Full Text] [Related]
29. Janus kinase 2: a critical target in chronic myelogenous leukemia. Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614 [TBL] [Abstract][Full Text] [Related]
30. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
31. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition. Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517 [TBL] [Abstract][Full Text] [Related]
32. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Carter BZ; Mak DH; Cortes J; Andreeff M Semin Hematol; 2010 Oct; 47(4):362-70. PubMed ID: 20875553 [TBL] [Abstract][Full Text] [Related]
33. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]